Abstract:Therapeutic antibodies must have "drug-like" properties. These include high affinity and specificity for the intended target, biological activity, and additional characteristics now known as "developability properties": long-term stability and resistance to aggregation when in solution, thermodynamic stability to prevent unfolding, high expression yields to facilitate manufacturing, low self-interaction, among others. Sequence-based liabilities may affect one or more of these characteristics. Improving the stability and developability of a lead antibody is typically achieved by modifying its sequence, a time-consuming process that often results in reduced affinity. Here we present a new antibody library format that yields high-affinity binders with drug-like developability properties directly from initial selections, reducing the need for further engineering or affinity maturation. The innovative semi-synthetic design involves grafting natural complementarity-determining regions (CDRs) from human antibodies into scaffolds based on well-behaved clinical antibodies. HCDR3s were amplified directly from B cells, while the remaining CDRs, from which all sequence liabilities had been purged, were replicated from a large next-generation sequencing dataset. By combining two in vitro display techniques, phage and yeast display, we were able to routinely recover a large number of unique, highly developable antibodies against clinically relevant targets with affinities in the subnanomolar to low nanomolar range. We anticipate that the designs and approaches presented here will accelerate the drug development process by reducing the failure rate of leads due to poor antibody affinities and developability.Abbreviations: AC-SINS: affinity-capture self-interaction nanoparticle spectroscopy; CDR: complementarity-determining region; CQA: critical quality attribute; ELISA: enzyme-linked immunoassay; FACS: fluorescence-activated cell sorting; Fv: fragment variable; GM-CSF: granulocyte-macrophage colony-stimulating factor; HCDR3: heavy chain CDR3; IFN2a: interferon α-2; IL6: interleukin-6; MACS: magnetic-activated cell sorting; NGS: next generation sequencing; PCR: polymerase chain reaction; SEC: size-exclusion chromatography; SPR: surface plasmon resonance; TGFβ-R2: transforming growth factor β-R2; VH: variable heavy; VK: variable kappa; VL: variable light; Vl: variable lambda.

Next generation antibody drugs: pursuit of the 'high-hanging fruit'

New Horizons in Therapeutic Antibody Discovery: Opportunities and Challenges versus Small-Molecule Therapeutics

The Dawn of a New Era: Targeting the "Undruggables" with Antibody-Based Therapeutics.

Antibody Conjugates-Recent Advances and Future Innovations

The role of therapeutic antibodies in drug discovery

Antibody-drug conjugates: prospects for the next generation

Discovery of Therapeutic Antibodies Targeting Complex Multi-Spanning Membrane Proteins

Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries

Antibodies and associates: Partners in targeted drug delivery

Strategies and challenges for the next generation of antibody–drug conjugates

Back to the future: recombinant polyclonal antibody therapeutics

Macromolecules and Antibody-Based Drugs.

Antibodies to watch in 2016

Antibodies to watch in 2015

Building better monoclonal antibody-based therapeutics

Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges

A review of antibody-based therapeutics targeting G protein-coupled receptors: an update

Better safe than sorry: dual targeting antibodies for cancer immunotherapy

Development of therapeutic antibodies for the treatment of diseases

Monoclonal antibodies: technologies for early discovery and engineering

Discovery and design of G protein-coupled receptor targeting antibodies